Search Results

You are looking at 21 - 30 of 43 items for :

  • "nephrectomy" x
Clear All
Full access

.2019.7345 Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy Palumbo Carlotta a b MD Mistretta Francesco A. a c MD Knipper Sophie a d MD Pecoraro Angela a e MD Tian Zhe a PhD

Full access

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke and Sandy Srinivas

characteristics and tumor features that could predict for benefit of cytokine therapy, including a favorable score on the University of California Los Angeles (UCLA) Survival After Nephrectomy and Immunotherapy (SANI) scale; clear cell histology; and carbonic

Full access

Elizabeth R. Plimack and Gary R. Hudes

, accounting for 80% of RCCs, and has the most data available. Cytoreductive nephrectomy should be considered for patients with clear cell histology and good performance status who are appropriate surgical candidates. This recommendation is based on 2

Full access

Patricia Thompson and Mayer Fishman

with renal cell carcinoma . J Clin Oncol 2002 ; 20 : 1368 – 1374 . 6 Flanigan RC Mickisch G Sylvester R . Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis . J Urol 2004 ; 171 : 1071 – 1076

Full access

Matthew Zibelman and Elizabeth R. Plimack

point of disease-free survival (DFS) versus placebo in patients after curative-intent nephrectomy, but unfortunately with no discernable effect on overall survival (OS) to date. 6 Without clear evidence-based data from randomized trials to guide

Full access

Daniel B. Brown

carcinoma for surgical candidates with suboptimal health, and outcomes appear similar to those of partial nephrectomy for patients with T1a tumors. Transarterial therapies are recommended for progressive liver metastases in many patients with neuroendocrine

Full access

Daniel Y. C. Heng and Toni K. Choueiri

and prognostic features among histologic subtypes of renal cell carcinoma . Am J Surg Pathol 2003 ; 27 : 612 – 624 . 5 Beck SD Patel MI Snyder ME . Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy

Full access

Yuefeng Wang, Xinhua Yu, Nan Zhao, Jiajing Wang, Chi Lin, Enrique W. Izaguirre, Michael Farmer, Gary Tian, Bradley Somer, Nilesh Dubal, David L. Schwartz, Matthew T. Ballo and Noam A. VanderWalde

-cell lung cancer: a phase 3 randomised controlled trial . Lancet 2015 ; 385 : 36 – 42 . 11. Mickisch GH Garin A van Poppel H . Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal

Full access

Eric Jonasch

. Adjuvant sunitinib in high-risk renal cell carcinoma after nephrectomy . N Engl J Med 2016 ; 375 : 2246 – 2254 . 3. Motzer RJ Hutson TE Tomczak P . Sunitinib versus interferon alfa in metastatic renal cell carcinoma . N Engl J Med 2007

Full access

Eric Jonasch and Robert J. Motzer

, endothelial, and stromal compartments as a function of therapy. Trial designs that permit acquisition of useful material include presurgical and sequential studies. The former can acquire nephrectomy specimens that have undergone changes as a function of